Literature DB >> 11145957

Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation.

K Park1, C B Verchere.   

Abstract

Islet amyloid deposits are a characteristic pathologic lesion of the pancreas in type 2 diabetes and are composed primarily of the islet beta cell peptide islet amyloid polypeptide (IAPP or amylin) as well as the basement membrane heparan sulfate proteoglycan perlecan. Impaired processing of the IAPP precursor has been implicated in the mechanism of islet amyloid formation. The N- and C-terminal cleavage sites where pro-IAPP is processed by prohormone convertases contain a series of basic amino acid residues that we hypothesized may interact with heparan sulfate proteoglycans. This possibility was tested using affinity chromatography by applying synthetic fragments of pro-IAPP to heparin-agarose and heparan sulfate-Sepharose. An N-terminal human pro-IAPP fragment (residues 1-30) was retained by both heparin-agarose and heparan sulfate-Sepharose, eluting at 0.18 m NaCl at pH 7.5. Substitution of alanine residues for two basic residues in the N-terminal cleavage site abolished heparin and heparan sulfate binding activity. At pH 5.5, the affinity of the wild-type peptide for heparin/heparan sulfate was increased, implying a role for histidine residues at positions 6 and 28 of pro-IAPP. A C-terminal pro-IAPP fragment (residues 41-67) had no specific affinity for either heparin or heparan sulfate, and the N- or C-terminal fragments had only weak affinity for chondroitin sulfate. These data suggest that monomeric N-terminal human pro-IAPP contains a heparin binding domain that is lost during normal processing of pro-IAPP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145957     DOI: 10.1074/jbc.M008423200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Reverse engineering an amyloid aggregation pathway with dimensional analysis and scaling.

Authors:  J Bailey; K J Potter; C B Verchere; L Edelstein-Keshet; D Coombs
Journal:  Phys Biol       Date:  2011-11-25       Impact factor: 2.583

2.  Inhibition of glycosaminoglycan-mediated amyloid formation by islet amyloid polypeptide and proIAPP processing intermediates.

Authors:  Fanling Meng; Daniel P Raleigh
Journal:  J Mol Biol       Date:  2010-12-30       Impact factor: 5.469

3.  Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide.

Authors:  Y J Park; S Lee; T J Kieffer; G L Warnock; N Safikhan; M Speck; Z Hao; M Woo; L Marzban
Journal:  Diabetologia       Date:  2012-02-01       Impact factor: 10.122

4.  Determination of the primary structure and carboxyl pK (A)s of heparin-derived oligosaccharides by band-selective homonuclear-decoupled two-dimensional (1)H NMR.

Authors:  Khanh Nguyen; Dallas L Rabenstein
Journal:  Anal Bioanal Chem       Date:  2010-10-03       Impact factor: 4.142

5.  Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3.

Authors:  E Law; S Lu; T J Kieffer; G L Warnock; Z Ao; M Woo; L Marzban
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

Review 6.  Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity.

Authors:  Ping Cao; Peter Marek; Harris Noor; Vadim Patsalo; Ling-Hsien Tu; Hui Wang; Andisheh Abedini; Daniel P Raleigh
Journal:  FEBS Lett       Date:  2013-02-01       Impact factor: 4.124

7.  A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation.

Authors:  Elodie Monsellier; Matteo Ramazzotti; Niccolò Taddei; Fabrizio Chiti
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

8.  Amyloid formation in heterogeneous environments: islet amyloid polypeptide glycosaminoglycan interactions.

Authors:  Hui Wang; Ping Cao; Daniel P Raleigh
Journal:  J Mol Biol       Date:  2012-11-12       Impact factor: 5.469

Review 9.  Mechanisms of islet amyloidosis toxicity in type 2 diabetes.

Authors:  Andisheh Abedini; Ann Marie Schmidt
Journal:  FEBS Lett       Date:  2013-01-18       Impact factor: 4.124

Review 10.  Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?

Authors:  A Clark; M R Nilsson
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.